Drug survival of interleukin 17 inhibitors after switch from interleukin 23 inhibitors in psoriasis: An observational cohort study

被引：0

作者：

Kushnir-Grinbaum, Daniella ^{[1
,2
]}

Ziv, Michael ^{[1
]}

机构：

[1] Techn Inst Technol, Rappaport Fac Med, Emek Med Ctr, Dermatol Dept, Afula, Israel

[2] Sinclair Dermatol, East Melbourne, Vic, Australia

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 06期

关键词：

anti IL-17; anti IL-23; bio experienced; biologics; drug survival; guselkumab; IL-17; inhibitor; IL-23; interleukin-17;

D O I：

10.1016/j.jaad.2024.07.1514

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：1260 / 1263

页数：4

共 50 条

[41] Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network
Tsai, Sung Huang Laurent
Yang, Chi-Ya
Huo, An-Ping
Wei, James Cheng-Chung
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (05) : 889 - 895
[42] Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
Wasilewska, Agnieszka
Winiarska, Marta
Olszewska, Malgorzata
Rudnicka, Lidia
POSTEPY DERMATOLOGII I ALERGOLOGII, 2016, 33 (04): : 247 - 252
[43] Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Thomas, Sarah E.
Barenbrug, Liana
Hannink, Gerjon
Seyger, Marieke M. B.
de Jong, Elke M. G. J.
van den Reek, Juul M. P. A.
DRUGS, 2024, 84 (05) : 565 - 578
[44] Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network
Strunz, Patrick-Pascal
Englbrecht, Matthias
Risser, Linus Maximilian
Witte, Torsten
Froehlich, Matthias
Schmalzing, Marc
Gernert, Michael
Schmieder, Astrid
Bartz-Bazzanella, Peter
von der Decken, Cay
Karberg, Kirsten
Gauler, Georg
Wurth, Patrick
Spaethling-Mestekemper, Susanna
Kuhn, Christoph
Vorbrueggen, Wolfgang
Heck, Johannes
Welcker, Martin
Kleinert, Stefan
RHEUMATOLOGY INTERNATIONAL, 2024, : 2057 - 2066
[45] Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis
Egeberg, A.
BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 247 - 248
[46] Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
Dapavo, Paolo
Siliquini, Niccolo
Mastorino, Luca
Avallone, Gianluca
Merli, Martina
Agostini, Andrea
Cariti, Caterina
Viola, Riccardo
Stroppiana, Elena
Verrone, Anna
Ortoncelli, Michela
Quaglino, Pietro
Ribero, Simone
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2352 - 2357
[47] Interleukin-23 inhibitors for the treatment of psoriasis in the UK: Early experience of a single secondary care department
Livesey, Amy
Cooper, Hywel
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB103 - AB103
[48] Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review
Salimi, Sohrab
Yamauchi, Paul S.
Thakur, Rohini
Weinberg, Jeffrey M.
Kircik, Leon
Abdelmaksoud, Ayman
Wollina, Uwe
Lotti, Torello
Sharma, Aseem
Grabbe, Stephan
Goldust, Mohamad
DERMATOLOGIC THERAPY, 2020, 33 (04)
[49] Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers
Luigi Gargiulo
Luciano Ibba
Mario Valenti
Diego Orsini
Antonio Cristaudo
Pasquale Frascione
Antonio Costanzo
Alessandra Narcisi
Clinical Drug Investigation, 2023, 43 : 807 - 812
[50] Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
Anisha B. Dua
Kerri Ford
Stefano Fiore
Dimitrios A. Pappas
Jud C. Janak
Taylor Blachley
Carla Roberts-Toler
Kelechi Emeanuru
Joel M. Kremer
Alan Kivitz
Rheumatology and Therapy, 2023, 10 : 1753 - 1768

← 1 2 3 4 5 →